Document is current
Any future updates will be listed below
-
Authors
Degrauwe, Sophie
Pilgrim, Thomas
Aminian, Adel
Noble, Stephane
Meier, Pascal
Iglesias, Juan F
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02619760 at ClinicalTrials.govnct02079194 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
https://doi.org/10.1161/circinterventions.122.012004
Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort
https://doi.org/10.1161/circinterventions.125.016280
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial
https://doi.org/10.1161/circinterventions.120.010384
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
https://doi.org/10.1007/s12928-020-00719-6
nct01813435 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor (Results)
https://doi.org/10.1136/heartjnl-2020-318821
nct02270242 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention
https://doi.org/10.1161/circinterventions.120.009177
Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
https://doi.org/10.1136/heartjnl-2015-309022
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54
https://doi.org/10.1136/heartjnl-2015-307858
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
https://doi.org/10.1161/circoutcomes.120.006660
The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
https://doi.org/10.1007/s00392-020-01604-1
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
https://doi.org/10.1186/s12933-020-01153-x
Coronary revascularisation in the elderly
https://doi.org/10.1136/heartjnl-2015-308999
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) (Results)
https://doi.org/10.1136/bmjopen-2018-026053
Characterization of quantitative flow ratio and fractional flow reserve discordance using doppler flow and clinical follow-up
https://doi.org/10.1007/s10554-022-02522-1
Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?
https://doi.org/10.1136/openhrt-2024-003083
Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence
https://doi.org/10.1016/j.clinthera.2016.02.016
nct02099617 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
https://doi.org/10.1136/heartjnl-2015-309022
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54
https://doi.org/10.1136/heartjnl-2015-307858
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy
https://doi.org/10.1161/circinterventions.120.009495
Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence
https://doi.org/10.1016/j.clinthera.2016.02.016
nct03023020 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
nct01755520 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
https://doi.org/10.1161/circulationaha.121.056680
nct02118870 at ClinicalTrials.govDocuments that mention this clinical trial
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial
https://doi.org/10.1016/j.ahj.2016.05.017
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
nct01701453 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
https://doi.org/10.1016/j.ahj.2016.04.016
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team—safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial
https://doi.org/10.1016/j.ahj.2016.07.022
Documents that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team—safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial
https://doi.org/10.1016/j.ahj.2016.07.022
